Stockscreener 앱 받기
2.50
1.21%
0.03
시간 외 거래:
2.50
전일 마감가:
$2.47
열려 있는:
$2.5
하루 거래량:
762.27K
Relative Volume:
0.49
시가총액:
$424.85M
수익:
-
순이익/손실:
$-236.30M
주가수익비율:
-1.7085
EPS:
-1.4633
순현금흐름:
$-208.07M
1주 성능:
-5.30%
1개월 성능:
-27.75%
6개월 성능:
+47.06%
1년 성능:
+119.30%
1일 변동 폭
$2.465
$2.615
1주일 범위
$2.41
$2.63
52주 변동 폭
$0.611
$3.65
Neumora Therapeutics Inc Stock (NMRA) Company Profile
명칭
Neumora Therapeutics Inc
전화
(857) 760-0900
주소
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
2.50 | 419.75M | 0 | -236.30M | -208.07M | -1.4633 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-17 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2026-01-12 | 개시 | Leerink Partners | Outperform |
| 2025-12-01 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-09-16 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-04-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2025-03-10 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Hold |
| 2023-10-10 | 개시 | BofA Securities | Buy |
| 2023-10-10 | 개시 | Guggenheim | Buy |
| 2023-10-10 | 개시 | JP Morgan | Overweight |
| 2023-10-10 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-10 | 개시 | Stifel | Buy |
| 2023-10-10 | 개시 | William Blair | Outperform |
모두보기
Neumora Therapeutics Inc 주식(NMRA)의 최신 뉴스
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the ... - Bluefield Daily Telegraph
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Neumora Therapeutic (NMRA.US) will release its earnings report on March 30. - Moomoo
If You Invested $1,000 in Neumora Therapeutics Inc (NMRA) - Stock Titan
Neumora Therapeutics stock jumps, analyst sees upside in Alzheimer's treatment - MSN
NMRA SEC FilingsNeumora Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neumora Therapeutics (NMRA) positioned to capitalize on blockbuster opportunity - MSN
Quarterly Trades: Is Neumora Therapeutics Inc forming a breakout pattern2026 Investor Takeaways & Daily Profit Maximizing Tips - baoquankhu1.vn
RBC sees upside potential in Neumora Therapeutics (NMRA) - MSN
Neumora reports promising Phase 1b results in Alzheimer’s agitation - MSN
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Short Interest Down 13.7% in February - MarketBeat
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026 - The Manila Times
Neuropsych Drugmaker Wants Out Of Investors' IPO Data Suit - Law360
Neumora Therapeutics (NASDAQ:NMRA) Stock Price Up 8.2%What's Next? - MarketBeat
Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity - Bitget
Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 - Finviz
Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements - Bitget
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
GSA Capital Partners LLP Cuts Stake in Neumora Therapeutics - National Today
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap DownTime to Sell? - MarketBeat
GSA Capital Partners LLP Cuts Position in Neumora Therapeutics, Inc. $NMRA - MarketBeat
Winners Losers: Will Neumora Therapeutics Inc benefit from geopolitical trends2025 Market WrapUp & Reliable Entry Point Trade Alerts - baoquankhu1.vn
AlphaCore Capital LLC Has $1.16 Million Stock Holdings in Neumora Therapeutics, Inc. $NMRA - MarketBeat
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Larimar Therapeutics (LRMR) and Cigna (CI) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Day One Biopharmaceuticals (DAWN) and Xenon (XENE) - The Globe and Mail
Neumora Therapeutics (NMRA) Projected to Post Earnings on Monday - MarketBeat
Neumora cut to Hold at Stifel after J&J’s VENTURA exit - MSN
Can Neumora Therapeutics Inc. stock withstand economic slowdownJuly 2025 Snapshot & Weekly Setup with High ROI Potential - mfd.ru
Risk Recap: Is Telomir Pharmaceuticals Inc stock a buy or sellFed Meeting & Smart Allocation Stock Tips - baoquankhu1.vn
Neumora Therapeutics CFO Milligan sells $5119 in shares By Investing.com - Investing.com Australia
Neumora Therapeutics CFO Milligan sells $5119 in shares - Investing.com
Top Neumora Executives Quietly Cash Out in Coordinated Stock Sell-Off - TipRanks
Insider Sell Alert: Michael Milligan Sells Shares of Neumora The - GuruFocus
Neumora Therapeutics (NASDAQ:NMRA) Insider Paul Berns Sells 9,819 Shares - MarketBeat
Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 6,165 Shares of Stock - MarketBeat
Trading Recap: Will Neumora Therapeutics Inc stock go up in YEARTake Profit & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Neumora Therapeutics advances in novel brain-penetrant therapies - Traders Union
Neumora Therapeutics (NASDAQ:NMRA) Hits New 12-Month High Following Analyst Upgrade - MarketBeat
William Blair upgrades Neumora Therapeutics (NMRA) - MSN
William Blair Upgrades Neumora Therapeutics (NMRA) - Nasdaq
Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment - Benzinga
Neumora Therapeutics Shares Rise After William Blair Upgrade - marketscreener.com
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Up After Analyst Upgrade - MarketBeat
William Blair Upgrades Neumora Therapeutics to Outperform From Market Perform - marketscreener.com
Neumora Therapeutics (NASDAQ:NMRA) Rating Increased to Outperform at William Blair - MarketBeat
Will Neumora Therapeutics Inc. stock go up in YEAR2025 Trading Recap & Fast Entry Momentum Trade Alerts - mfd.ru
Neumora Therapeutics Inc (NMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):